RapamycinFungusV1, Main, Exploration, bibRecord, 000084

Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes.

Identifieur interne : 000084 ( Main/Exploration ); précédent : 000083; suivant : 000085

Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes.

Auteurs : Wipawee Saenwongsa [Thaïlande] ; Arnone Nithichanon [Thaïlande] ; Malinee Chittaganpitch [Thaïlande] ; Kampaew Buayai [Thaïlande] ; Chidchamai Kewcharoenwong [Thaïlande] ; Boonyarat Thumrongwilainet [Thaïlande] ; Patcharavadee Butta [Thaïlande] ; Tanapat Palaga [Thaïlande] ; Yoshimasa Takahashi [Japon] ; Manabu Ato [Japon] ; Ganjana Lertmemongkolchai [Thaïlande]

Source :

Scientific reports [ 2045-2322 ] ; 2020.

RBID : pubmed:32094377

Descripteurs français

English descriptors

KwdEn :
- Aged (MeSH), Antibodies, Viral (immunology), Antibody Affinity (immunology), Antibody Formation (drug effects), Diabetes Mellitus, Type 2 (drug therapy), Diabetes Mellitus, Type 2 (immunology), Female (MeSH), Glyburide (pharmacology), Glyburide (therapeutic use), Hemagglutination Inhibition Tests (MeSH), Humans (MeSH), Immunoglobulin G (metabolism), Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H3N2 Subtype (drug effects), Influenza A Virus, H3N2 Subtype (immunology), Influenza B virus (drug effects), Influenza B virus (immunology), Influenza Vaccines (immunology), Interferon-alpha (pharmacology), Male (MeSH), Mechanistic Target of Rapamycin Complex 1 (metabolism), Metformin (pharmacology), Metformin (therapeutic use), Monocytes (drug effects), Monocytes (metabolism), Seasons (MeSH), Signal Transduction (drug effects), Vaccination (MeSH), Virion (drug effects), Virion (immunology).
MESH :
- chemical , immunology : Antibodies, Viral, Influenza Vaccines.
- drug effects : Antibody Formation, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus, Monocytes, Signal Transduction, Virion.
- drug therapy : Diabetes Mellitus, Type 2.
- immunology : Antibody Affinity, Diabetes Mellitus, Type 2, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus, Virion.
- chemical , metabolism : Immunoglobulin G, Mechanistic Target of Rapamycin Complex 1, Monocytes.
- chemical , pharmacology : Glyburide, Interferon-alpha, Metformin.
- chemical , therapeutic use : Glyburide, Metformin.
- Aged, Female, Hemagglutination Inhibition Tests, Humans, Male, Seasons, Vaccination.

Abstract

Diabetes mellitus (DM) patients are at an increased risk of complications following influenza-virus infection, seasonal vaccination (SV) is recommended. However, SV with trivalent influenza vaccine (TIV) can induce antibody and type-I interferon (IFN) responses, and the effect of anti-DM treatment on these responses is incompletely understood. We evaluated the antibody response and IFN-α expression in individuals with and without type 2 DM (T2DM) following SV, and examined the effects on anti-DM treatment. TIV elicited sero-protection in all groups, but antibody persistency was <8 months, except for the antibody response to B-antigens in non-DM. T2DM impaired the IgG avidity index, and T2DM showed a significantly decreased response against H1N1 and H3N2, in addition to delaying and reducing haemagglutination-inhibition persistency against influenza B-antigens in DM groups treated with metformin (Met-DM) or glibenclamide (GB-DM). Following TIV, the Met-DM and GB-DM groups exhibited reduced IFN-α expression upon stimulation with whole- and split-virion influenza vaccines. Suppression of IFN-α expression in the Met-DM group was associated with a reduction in the mechanistic target of rapamycin complex-1 pathway and impaired IgG avidity index. Thus, single-dose TIV each year might not be suitable for T2DM. Our data could aid the development of an efficacious influenza vaccine for T2DM.

DOI: 10.1038/s41598-020-60213-0
PubMed: 32094377
PubMed Central: PMC7039947

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000110
to stream Main, to step Curation: 000110

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes.</title>
<author><name sortKey="Saenwongsa, Wipawee" sort="Saenwongsa, Wipawee" uniqKey="Saenwongsa W" first="Wipawee" last="Saenwongsa">Wipawee Saenwongsa</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen</wicri:regionArea>
<wicri:noRegion>Khon Kaen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Disease Prevention and Control Region 10th, Ubonratchathani, Ministry of Public Health, Mueang Nonthaburi, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Disease Prevention and Control Region 10th, Ubonratchathani, Ministry of Public Health, Mueang Nonthaburi</wicri:regionArea>
<wicri:noRegion>Mueang Nonthaburi</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nithichanon, Arnone" sort="Nithichanon, Arnone" uniqKey="Nithichanon A" first="Arnone" last="Nithichanon">Arnone Nithichanon</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen</wicri:regionArea>
<wicri:noRegion>Khon Kaen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chittaganpitch, Malinee" sort="Chittaganpitch, Malinee" uniqKey="Chittaganpitch M" first="Malinee" last="Chittaganpitch">Malinee Chittaganpitch</name>
<affiliation wicri:level="1"><nlm:affiliation>National Influenza Centre, Department of Medical Science, Ministry of Public Health, Mueang Nonthaburi, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>National Influenza Centre, Department of Medical Science, Ministry of Public Health, Mueang Nonthaburi</wicri:regionArea>
<wicri:noRegion>Mueang Nonthaburi</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Buayai, Kampaew" sort="Buayai, Kampaew" uniqKey="Buayai K" first="Kampaew" last="Buayai">Kampaew Buayai</name>
<affiliation wicri:level="1"><nlm:affiliation>National Influenza Centre, Department of Medical Science, Ministry of Public Health, Mueang Nonthaburi, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>National Influenza Centre, Department of Medical Science, Ministry of Public Health, Mueang Nonthaburi</wicri:regionArea>
<wicri:noRegion>Mueang Nonthaburi</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kewcharoenwong, Chidchamai" sort="Kewcharoenwong, Chidchamai" uniqKey="Kewcharoenwong C" first="Chidchamai" last="Kewcharoenwong">Chidchamai Kewcharoenwong</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen</wicri:regionArea>
<wicri:noRegion>Khon Kaen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thumrongwilainet, Boonyarat" sort="Thumrongwilainet, Boonyarat" uniqKey="Thumrongwilainet B" first="Boonyarat" last="Thumrongwilainet">Boonyarat Thumrongwilainet</name>
<affiliation wicri:level="1"><nlm:affiliation>Yanglum Health Promotion Hospital, Ubonratchathani, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Yanglum Health Promotion Hospital, Ubonratchathani</wicri:regionArea>
<wicri:noRegion>Ubonratchathani</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Butta, Patcharavadee" sort="Butta, Patcharavadee" uniqKey="Butta P" first="Patcharavadee" last="Butta">Patcharavadee Butta</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Palaga, Tanapat" sort="Palaga, Tanapat" uniqKey="Palaga T" first="Tanapat" last="Palaga">Tanapat Palaga</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Takahashi, Yoshimasa" sort="Takahashi, Yoshimasa" uniqKey="Takahashi Y" first="Yoshimasa" last="Takahashi">Yoshimasa Takahashi</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute of Infectious Diseases, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>National Institute of Infectious Diseases, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ato, Manabu" sort="Ato, Manabu" uniqKey="Ato M" first="Manabu" last="Ato">Manabu Ato</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute of Infectious Diseases, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>National Institute of Infectious Diseases, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lertmemongkolchai, Ganjana" sort="Lertmemongkolchai, Ganjana" uniqKey="Lertmemongkolchai G" first="Ganjana" last="Lertmemongkolchai">Ganjana Lertmemongkolchai</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand. ganja_le@kku.ac.th.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen</wicri:regionArea>
<wicri:noRegion>Khon Kaen</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32094377</idno>
<idno type="pmid">32094377</idno>
<idno type="doi">10.1038/s41598-020-60213-0</idno>
<idno type="pmc">PMC7039947</idno>
<idno type="wicri:Area/Main/Corpus">000110</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000110</idno>
<idno type="wicri:Area/Main/Curation">000110</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000110</idno>
<idno type="wicri:Area/Main/Exploration">000110</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes.</title>
<author><name sortKey="Saenwongsa, Wipawee" sort="Saenwongsa, Wipawee" uniqKey="Saenwongsa W" first="Wipawee" last="Saenwongsa">Wipawee Saenwongsa</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen</wicri:regionArea>
<wicri:noRegion>Khon Kaen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Disease Prevention and Control Region 10th, Ubonratchathani, Ministry of Public Health, Mueang Nonthaburi, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Disease Prevention and Control Region 10th, Ubonratchathani, Ministry of Public Health, Mueang Nonthaburi</wicri:regionArea>
<wicri:noRegion>Mueang Nonthaburi</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nithichanon, Arnone" sort="Nithichanon, Arnone" uniqKey="Nithichanon A" first="Arnone" last="Nithichanon">Arnone Nithichanon</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen</wicri:regionArea>
<wicri:noRegion>Khon Kaen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chittaganpitch, Malinee" sort="Chittaganpitch, Malinee" uniqKey="Chittaganpitch M" first="Malinee" last="Chittaganpitch">Malinee Chittaganpitch</name>
<affiliation wicri:level="1"><nlm:affiliation>National Influenza Centre, Department of Medical Science, Ministry of Public Health, Mueang Nonthaburi, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>National Influenza Centre, Department of Medical Science, Ministry of Public Health, Mueang Nonthaburi</wicri:regionArea>
<wicri:noRegion>Mueang Nonthaburi</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Buayai, Kampaew" sort="Buayai, Kampaew" uniqKey="Buayai K" first="Kampaew" last="Buayai">Kampaew Buayai</name>
<affiliation wicri:level="1"><nlm:affiliation>National Influenza Centre, Department of Medical Science, Ministry of Public Health, Mueang Nonthaburi, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>National Influenza Centre, Department of Medical Science, Ministry of Public Health, Mueang Nonthaburi</wicri:regionArea>
<wicri:noRegion>Mueang Nonthaburi</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kewcharoenwong, Chidchamai" sort="Kewcharoenwong, Chidchamai" uniqKey="Kewcharoenwong C" first="Chidchamai" last="Kewcharoenwong">Chidchamai Kewcharoenwong</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen</wicri:regionArea>
<wicri:noRegion>Khon Kaen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thumrongwilainet, Boonyarat" sort="Thumrongwilainet, Boonyarat" uniqKey="Thumrongwilainet B" first="Boonyarat" last="Thumrongwilainet">Boonyarat Thumrongwilainet</name>
<affiliation wicri:level="1"><nlm:affiliation>Yanglum Health Promotion Hospital, Ubonratchathani, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Yanglum Health Promotion Hospital, Ubonratchathani</wicri:regionArea>
<wicri:noRegion>Ubonratchathani</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Butta, Patcharavadee" sort="Butta, Patcharavadee" uniqKey="Butta P" first="Patcharavadee" last="Butta">Patcharavadee Butta</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Palaga, Tanapat" sort="Palaga, Tanapat" uniqKey="Palaga T" first="Tanapat" last="Palaga">Tanapat Palaga</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Takahashi, Yoshimasa" sort="Takahashi, Yoshimasa" uniqKey="Takahashi Y" first="Yoshimasa" last="Takahashi">Yoshimasa Takahashi</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute of Infectious Diseases, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>National Institute of Infectious Diseases, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ato, Manabu" sort="Ato, Manabu" uniqKey="Ato M" first="Manabu" last="Ato">Manabu Ato</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute of Infectious Diseases, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>National Institute of Infectious Diseases, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lertmemongkolchai, Ganjana" sort="Lertmemongkolchai, Ganjana" uniqKey="Lertmemongkolchai G" first="Ganjana" last="Lertmemongkolchai">Ganjana Lertmemongkolchai</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand. ganja_le@kku.ac.th.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen</wicri:regionArea>
<wicri:noRegion>Khon Kaen</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Scientific reports</title>
<idno type="eISSN">2045-2322</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antibody Affinity (immunology)</term>
<term>Antibody Formation (drug effects)</term>
<term>Diabetes Mellitus, Type 2 (drug therapy)</term>
<term>Diabetes Mellitus, Type 2 (immunology)</term>
<term>Female (MeSH)</term>
<term>Glyburide (pharmacology)</term>
<term>Glyburide (therapeutic use)</term>
<term>Hemagglutination Inhibition Tests (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunoglobulin G (metabolism)</term>
<term>Influenza A Virus, H1N1 Subtype (drug effects)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H3N2 Subtype (drug effects)</term>
<term>Influenza A Virus, H3N2 Subtype (immunology)</term>
<term>Influenza B virus (drug effects)</term>
<term>Influenza B virus (immunology)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Interferon-alpha (pharmacology)</term>
<term>Male (MeSH)</term>
<term>Mechanistic Target of Rapamycin Complex 1 (metabolism)</term>
<term>Metformin (pharmacology)</term>
<term>Metformin (therapeutic use)</term>
<term>Monocytes (drug effects)</term>
<term>Monocytes (metabolism)</term>
<term>Seasons (MeSH)</term>
<term>Signal Transduction (drug effects)</term>
<term>Vaccination (MeSH)</term>
<term>Virion (drug effects)</term>
<term>Virion (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Affinité des anticorps (immunologie)</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Complexe-1 cible mécanistique de la rapamycine (métabolisme)</term>
<term>Diabète de type 2 (immunologie)</term>
<term>Diabète de type 2 (traitement médicamenteux)</term>
<term>Femelle (MeSH)</term>
<term>Glibenclamide (pharmacologie)</term>
<term>Glibenclamide (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Immunoglobuline G (métabolisme)</term>
<term>Interféron alpha (pharmacologie)</term>
<term>Metformine (pharmacologie)</term>
<term>Metformine (usage thérapeutique)</term>
<term>Monocytes (effets des médicaments et des substances chimiques)</term>
<term>Monocytes (métabolisme)</term>
<term>Mâle (MeSH)</term>
<term>Production d'anticorps (effets des médicaments et des substances chimiques)</term>
<term>Saisons (MeSH)</term>
<term>Sous-type H1N1 du virus de la grippe A (effets des médicaments et des substances chimiques)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H3N2 du virus de la grippe A (effets des médicaments et des substances chimiques)</term>
<term>Sous-type H3N2 du virus de la grippe A (immunologie)</term>
<term>Sujet âgé (MeSH)</term>
<term>Tests d'inhibition de l'hémagglutination (MeSH)</term>
<term>Transduction du signal (effets des médicaments et des substances chimiques)</term>
<term>Vaccination (MeSH)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Virion (effets des médicaments et des substances chimiques)</term>
<term>Virion (immunologie)</term>
<term>Virus influenza B (effets des médicaments et des substances chimiques)</term>
<term>Virus influenza B (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Antibody Formation</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza B virus</term>
<term>Monocytes</term>
<term>Signal Transduction</term>
<term>Virion</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Monocytes</term>
<term>Production d'anticorps</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Transduction du signal</term>
<term>Virion</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Affinité des anticorps</term>
<term>Anticorps antiviraux</term>
<term>Diabète de type 2</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Virion</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Affinity</term>
<term>Diabetes Mellitus, Type 2</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza B virus</term>
<term>Virion</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Immunoglobulin G</term>
<term>Mechanistic Target of Rapamycin Complex 1</term>
<term>Monocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Complexe-1 cible mécanistique de la rapamycine</term>
<term>Immunoglobuline G</term>
<term>Monocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Glibenclamide</term>
<term>Interféron alpha</term>
<term>Metformine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Glyburide</term>
<term>Interferon-alpha</term>
<term>Metformin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Glyburide</term>
<term>Metformin</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Glibenclamide</term>
<term>Metformine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Hemagglutination Inhibition Tests</term>
<term>Humans</term>
<term>Male</term>
<term>Seasons</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Saisons</term>
<term>Sujet âgé</term>
<term>Tests d'inhibition de l'hémagglutination</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Diabetes mellitus (DM) patients are at an increased risk of complications following influenza-virus infection, seasonal vaccination (SV) is recommended. However, SV with trivalent influenza vaccine (TIV) can induce antibody and type-I interferon (IFN) responses, and the effect of anti-DM treatment on these responses is incompletely understood. We evaluated the antibody response and IFN-α expression in individuals with and without type 2 DM (T2DM) following SV, and examined the effects on anti-DM treatment. TIV elicited sero-protection in all groups, but antibody persistency was <8 months, except for the antibody response to B-antigens in non-DM. T2DM impaired the IgG avidity index, and T2DM showed a significantly decreased response against H1N1 and H3N2, in addition to delaying and reducing haemagglutination-inhibition persistency against influenza B-antigens in DM groups treated with metformin (Met-DM) or glibenclamide (GB-DM). Following TIV, the Met-DM and GB-DM groups exhibited reduced IFN-α expression upon stimulation with whole- and split-virion influenza vaccines. Suppression of IFN-α expression in the Met-DM group was associated with a reduction in the mechanistic target of rapamycin complex-1 pathway and impaired IgG avidity index. Thus, single-dose TIV each year might not be suitable for T2DM. Our data could aid the development of an efficacious influenza vaccine for T2DM.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32094377</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>11</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>10</Volume>
<Issue>1</Issue>
<PubDate><Year>2020</Year>
<Month>02</Month>
<Day>24</Day>
</PubDate>
</JournalIssue>
<Title>Scientific reports</Title>
<ISOAbbreviation>Sci Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes.</ArticleTitle>
<Pagination><MedlinePgn>3229</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-60213-0</ELocationID>
<Abstract><AbstractText>Diabetes mellitus (DM) patients are at an increased risk of complications following influenza-virus infection, seasonal vaccination (SV) is recommended. However, SV with trivalent influenza vaccine (TIV) can induce antibody and type-I interferon (IFN) responses, and the effect of anti-DM treatment on these responses is incompletely understood. We evaluated the antibody response and IFN-α expression in individuals with and without type 2 DM (T2DM) following SV, and examined the effects on anti-DM treatment. TIV elicited sero-protection in all groups, but antibody persistency was <8 months, except for the antibody response to B-antigens in non-DM. T2DM impaired the IgG avidity index, and T2DM showed a significantly decreased response against H1N1 and H3N2, in addition to delaying and reducing haemagglutination-inhibition persistency against influenza B-antigens in DM groups treated with metformin (Met-DM) or glibenclamide (GB-DM). Following TIV, the Met-DM and GB-DM groups exhibited reduced IFN-α expression upon stimulation with whole- and split-virion influenza vaccines. Suppression of IFN-α expression in the Met-DM group was associated with a reduction in the mechanistic target of rapamycin complex-1 pathway and impaired IgG avidity index. Thus, single-dose TIV each year might not be suitable for T2DM. Our data could aid the development of an efficacious influenza vaccine for T2DM.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saenwongsa</LastName>
<ForeName>Wipawee</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Disease Prevention and Control Region 10th, Ubonratchathani, Ministry of Public Health, Mueang Nonthaburi, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nithichanon</LastName>
<ForeName>Arnone</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chittaganpitch</LastName>
<ForeName>Malinee</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>National Influenza Centre, Department of Medical Science, Ministry of Public Health, Mueang Nonthaburi, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Buayai</LastName>
<ForeName>Kampaew</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>National Influenza Centre, Department of Medical Science, Ministry of Public Health, Mueang Nonthaburi, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kewcharoenwong</LastName>
<ForeName>Chidchamai</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thumrongwilainet</LastName>
<ForeName>Boonyarat</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Yanglum Health Promotion Hospital, Ubonratchathani, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Butta</LastName>
<ForeName>Patcharavadee</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Palaga</LastName>
<ForeName>Tanapat</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Takahashi</LastName>
<ForeName>Yoshimasa</ForeName>
<Initials>Y</Initials>
<Identifier Source="ORCID">0000-0001-6342-4087</Identifier>
<AffiliationInfo><Affiliation>National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ato</LastName>
<ForeName>Manabu</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lertmemongkolchai</LastName>
<ForeName>Ganjana</ForeName>
<Initials>G</Initials>
<Identifier Source="ORCID">0000-0001-6972-585X</Identifier>
<AffiliationInfo><Affiliation>Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand. ganja_le@kku.ac.th.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>02</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Sci Rep</MedlineTA>
<NlmUniqueID>101563288</NlmUniqueID>
<ISSNLinking>2045-2322</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9100L32L2N</RegistryNumber>
<NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>SX6K58TVWC</RegistryNumber>
<NameOfSubstance UI="D005905">Glyburide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000915" MajorTopicYN="N">Antibody Affinity</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005905" MajorTopicYN="N">Glyburide</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>07</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>02</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32094377</ArticleId>
<ArticleId IdType="doi">10.1038/s41598-020-60213-0</ArticleId>
<ArticleId IdType="pii">10.1038/s41598-020-60213-0</ArticleId>
<ArticleId IdType="pmc">PMC7039947</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Immunity. 2017 Jun 20;46(6):1045-1058.e6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28636954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Recomm Rep. 2006 Jul 28;55(RR-10):1-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16874296</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Immunol. 2005 Jul;62(1):36-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16092921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2016 Nov 21;7:13254</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27869123</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2011 Feb 24;470(7335):543-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21350488</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2006 Sep;25(3):349-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16979567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2008 Oct;9(10):1157-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18758466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2014 Jan;14(1):36-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24362405</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Sci (Lond). 2012 Mar;122(6):253-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22117616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2019 Jan 18;68(3):382-392</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29893797</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trans R Soc Trop Med Hyg. 2019 Feb 1;113(2):56-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30517697</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2018 Sep 19;9:2109</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30283449</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2017 Sep 12;35(38):5095-5101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28807608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol. 2006 Oct;121(1):81-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16859998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Microbiol. 2017 May 22;8:861</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28588558</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Jul 27;30(35):5262-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22691431</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1997 Jun;15(9):962-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9261942</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2014 Apr 10;157(2):499-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24725414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2008 Mar 20;452(7185):323-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18272964</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2010 Oct;9(10):1127-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20923264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2013 Aug 15;191(4):1692-703</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23858034</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunology. 2017 May;151(1):98-109</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28066900</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2010 Oct 29;33(4):516-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21029962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunology. 2006 Jan;117(1):11-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16423036</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 2015;386:23-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25078919</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2014 Apr 10;157(2):294-299</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24725400</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 Oct 07;6:34794</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27713554</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Retrovirology. 2017 Apr 17;14(1):25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28415995</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2016 May 11;7:180</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27242787</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2007 Feb 15;178(4):2182-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17277123</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2005 Aug 1;41(3):281-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16007521</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2016 May 15;196(10):4172-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27053762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2010 Mar 31;2(25):25ra24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20424013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2014 Jul 3;511(7507):99-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24990750</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2011 Oct;7(10):e1002293</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21998589</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2010 Mar 1;398(1):109-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20034647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2017 Jan;40(1):3-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27999000</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Res Clin Pract. 2018 Apr;138:271-281</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29496507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kidney Int. 2010 May;77(10):848-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20237459</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Pathol. 2008;3:499-522</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18039138</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2014;10(5):1187-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24717236</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2018 Jun 04;9:1236</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29915588</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2015 Dec 15;43(6):1186-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26682988</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell Endocrinol. 2013 Jun 15;372(1-2):73-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23567548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2008 Feb 18;205(2):315-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18227218</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2016 Dec 22;11(12):e0168647</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28005949</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2015 Feb;15(2):87-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25614319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol Methods. 1980;39(1-2):71-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7462647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Biol. 2008 Nov;1(1-4):27-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19568796</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2013 Jul 15;191(2):810-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23761632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4808-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18339807</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Jun 26;33(29):3306-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26044491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2017 May 27;487(2):223-229</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28412370</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2015 Nov;22(11):1160-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26376926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Springer Semin Immunopathol. 2005 Jan;26(3):221-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15592841</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2008 Oct;9(10):1097-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18800159</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Res. 2016 Aug 19;119(5):652-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27418629</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2013 Dec;14(12):1266-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24141387</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Agents Med Chem. 2010 Sep;10(7):571-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20812900</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Japon</li>
<li>Thaïlande</li>
</country>
<region><li>Région de Kantō</li>
</region>
<settlement><li>Tokyo</li>
</settlement>
</list>
<tree><country name="Thaïlande"><noRegion><name sortKey="Saenwongsa, Wipawee" sort="Saenwongsa, Wipawee" uniqKey="Saenwongsa W" first="Wipawee" last="Saenwongsa">Wipawee Saenwongsa</name>
</noRegion>
<name sortKey="Buayai, Kampaew" sort="Buayai, Kampaew" uniqKey="Buayai K" first="Kampaew" last="Buayai">Kampaew Buayai</name>
<name sortKey="Butta, Patcharavadee" sort="Butta, Patcharavadee" uniqKey="Butta P" first="Patcharavadee" last="Butta">Patcharavadee Butta</name>
<name sortKey="Chittaganpitch, Malinee" sort="Chittaganpitch, Malinee" uniqKey="Chittaganpitch M" first="Malinee" last="Chittaganpitch">Malinee Chittaganpitch</name>
<name sortKey="Kewcharoenwong, Chidchamai" sort="Kewcharoenwong, Chidchamai" uniqKey="Kewcharoenwong C" first="Chidchamai" last="Kewcharoenwong">Chidchamai Kewcharoenwong</name>
<name sortKey="Lertmemongkolchai, Ganjana" sort="Lertmemongkolchai, Ganjana" uniqKey="Lertmemongkolchai G" first="Ganjana" last="Lertmemongkolchai">Ganjana Lertmemongkolchai</name>
<name sortKey="Nithichanon, Arnone" sort="Nithichanon, Arnone" uniqKey="Nithichanon A" first="Arnone" last="Nithichanon">Arnone Nithichanon</name>
<name sortKey="Palaga, Tanapat" sort="Palaga, Tanapat" uniqKey="Palaga T" first="Tanapat" last="Palaga">Tanapat Palaga</name>
<name sortKey="Saenwongsa, Wipawee" sort="Saenwongsa, Wipawee" uniqKey="Saenwongsa W" first="Wipawee" last="Saenwongsa">Wipawee Saenwongsa</name>
<name sortKey="Thumrongwilainet, Boonyarat" sort="Thumrongwilainet, Boonyarat" uniqKey="Thumrongwilainet B" first="Boonyarat" last="Thumrongwilainet">Boonyarat Thumrongwilainet</name>
</country>
<country name="Japon"><region name="Région de Kantō"><name sortKey="Takahashi, Yoshimasa" sort="Takahashi, Yoshimasa" uniqKey="Takahashi Y" first="Yoshimasa" last="Takahashi">Yoshimasa Takahashi</name>
</region>
<name sortKey="Ato, Manabu" sort="Ato, Manabu" uniqKey="Ato M" first="Manabu" last="Ato">Manabu Ato</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000084 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000084 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32094377
   |texte=   Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32094377" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes.

Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki